Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Gadolinium chelate.
It has been used in the pediatric and neonatal age.
The meglumine gadopentetate is excreted into breast milk in clinically non-significant (0.02% of the maternal dose) amount and there have been no problems in infants whose mothers had received this contrast medium (Rubik 2000, Rofsky 1993, Schmiedl 1990).
The various contrast media that are gadolinium derivatives and used for explorations with Magnetic Resonance Imaging (MRI) are considered compatible with breastfeeding because they are quickly eliminated (elimination half-life of less than 2 hours). They undergo very little metabolic changes and are virtually non-absorbable orally. They are structurally very similar to each other. Some have been shown to have no or minimal excretion into the milk (ACR 2018 p99, Wang 2012, Rubik 2000, Rofsky 1993).
Due to its low oral bioavailability, intestinal absorption should be less than 1% of the dose took by the infant.
The maximum dose received by the infant is much less than the dose administered to a newborn infant who undergoes a MRI scan.
Most Radiology Scientific Societies agree that after an MRI scan is not necessary to temporarily stop breastfeeding (ACR 2018 p99, Puac 2017, Cova 2014, Quintana 2014, Patenaude 2014, Sachs 2013, Tremblay 2012, Wang 2012, Chen 2008, Newman 2007, Webb 2005).
Some authors recommend avoiding the use on lactating women of some Gadolinium contrast media that would pose a high risk for developing Systemic Nephrogenic Fibrosis, especially in the neonatal period, like gadoversetamide, and gadodiamide dimeglumine, by using instead low-risk ones like gadoterate, gadoteridol and gadobutrol (Puac 2017, Quintana 2014, EMA 2010).
The American Academy of Pediatrics has classified it as usually compatible while breastfeeding (AAP 2001).